JP2020536492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536492A5 JP2020536492A5 JP2020511350A JP2020511350A JP2020536492A5 JP 2020536492 A5 JP2020536492 A5 JP 2020536492A5 JP 2020511350 A JP2020511350 A JP 2020511350A JP 2020511350 A JP2020511350 A JP 2020511350A JP 2020536492 A5 JP2020536492 A5 JP 2020536492A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims 59
- 102000004196 processed proteins & peptides Human genes 0.000 claims 59
- 239000000427 antigen Substances 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010046788 Uterine haemorrhage Diseases 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 208000002938 adenomyoma Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229960000106 biosimilars Drugs 0.000 claims 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549523P | 2017-08-24 | 2017-08-24 | |
| US62/549,523 | 2017-08-24 | ||
| US201762579287P | 2017-10-31 | 2017-10-31 | |
| US62/579,287 | 2017-10-31 | ||
| US201862656586P | 2018-04-12 | 2018-04-12 | |
| US62/656,586 | 2018-04-12 | ||
| US201862658111P | 2018-04-16 | 2018-04-16 | |
| US62/658,111 | 2018-04-16 | ||
| PCT/US2018/047144 WO2019040390A1 (en) | 2017-08-24 | 2018-08-21 | ANTI-APELIN ANTIBODIES AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536492A JP2020536492A (ja) | 2020-12-17 |
| JP2020536492A5 true JP2020536492A5 (enExample) | 2021-07-26 |
| JP7219265B2 JP7219265B2 (ja) | 2023-02-07 |
Family
ID=65440110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511350A Active JP7219265B2 (ja) | 2017-08-24 | 2018-08-21 | 抗アペリン抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11365242B2 (enExample) |
| EP (1) | EP3672987B1 (enExample) |
| JP (1) | JP7219265B2 (enExample) |
| KR (1) | KR20200038311A (enExample) |
| CN (1) | CN111032689B (enExample) |
| AU (1) | AU2018322452A1 (enExample) |
| BR (1) | BR112020003584A2 (enExample) |
| CA (1) | CA3072261A1 (enExample) |
| IL (1) | IL272476A (enExample) |
| MX (1) | MX2020002042A (enExample) |
| SG (1) | SG11202000899PA (enExample) |
| WO (1) | WO2019040390A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110655577A (zh) * | 2018-06-13 | 2020-01-07 | 鸿运华宁（杭州）生物医药有限公司 | APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 |
| WO2020257460A2 (en) * | 2019-06-19 | 2020-12-24 | Ab Initio Biotherapeutics, Inc. | Apj modulators and uses thereof |
| WO2021126538A1 (en) * | 2019-12-17 | 2021-06-24 | Phanes Therapeutics, Inc. | Bispecific antibodies with alternatively matched interchain cycteines and uses thereof |
| CN112442534B (zh) * | 2020-11-06 | 2022-03-15 | 温州医科大学 | 循环血外泌体miR-146a-5p作为视网膜静脉阻塞治疗及预后评估标志物中的应用 |
| CN114539415B (zh) * | 2020-11-24 | 2024-02-02 | 普米斯生物技术(珠海)有限公司 | 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途 |
| CN112480267A (zh) * | 2020-12-04 | 2021-03-12 | 复旦大学附属华山医院 | 一种可特异性识别增殖状态内皮细胞的启动分子及工程细胞 |
| CN112546198B (zh) * | 2020-12-17 | 2022-03-25 | 温州医科大学慈溪生物医药研究院 | 一种用于治疗脑中风和急性脑梗的药物组合物 |
| CN114099642A (zh) * | 2021-11-12 | 2022-03-01 | 南通大学 | 基因Apln在制备治疗与细胞成血管有关疾病药物中的应用 |
| CN114031686A (zh) * | 2021-12-23 | 2022-02-11 | 杭州百凌生物科技有限公司 | 一种四型胶原蛋白ɑ5的抗体、检测试剂盒及其应用 |
| CN120058948A (zh) * | 2023-11-30 | 2025-05-30 | 粤港澳大湾区精准医学研究院(广州) | 一种抗人her2的单克隆抗体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8946382B2 (en) | 2009-02-27 | 2015-02-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Apelin peptides and methods of use |
| WO2013012855A1 (en) * | 2011-07-18 | 2013-01-24 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
| US9593153B2 (en) | 2012-04-11 | 2017-03-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Modified apelin polypeptides |
| US9353163B2 (en) * | 2013-03-14 | 2016-05-31 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
| US9868777B2 (en) | 2013-06-10 | 2018-01-16 | Merck Sharp & Dohme Corp. | CMV neutralizing antigen binding proteins |
-
2018
- 2018-08-21 BR BR112020003584-0A patent/BR112020003584A2/pt not_active IP Right Cessation
- 2018-08-21 AU AU2018322452A patent/AU2018322452A1/en not_active Abandoned
- 2018-08-21 EP EP18848958.7A patent/EP3672987B1/en active Active
- 2018-08-21 CA CA3072261A patent/CA3072261A1/en active Pending
- 2018-08-21 WO PCT/US2018/047144 patent/WO2019040390A1/en not_active Ceased
- 2018-08-21 JP JP2020511350A patent/JP7219265B2/ja active Active
- 2018-08-21 MX MX2020002042A patent/MX2020002042A/es unknown
- 2018-08-21 SG SG11202000899PA patent/SG11202000899PA/en unknown
- 2018-08-21 CN CN201880055019.2A patent/CN111032689B/zh active Active
- 2018-08-21 KR KR1020207008305A patent/KR20200038311A/ko not_active Withdrawn
- 2018-08-21 US US16/639,808 patent/US11365242B2/en active Active
-
2020
- 2020-02-05 IL IL272476A patent/IL272476A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536492A5 (enExample) | ||
| JP6367233B2 (ja) | 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用 | |
| JP7531667B2 (ja) | リンパ球における阻害経路の中和 | |
| JP6606505B2 (ja) | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 | |
| JP7547581B2 (ja) | 腫瘍治療薬及びその応用 | |
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| CN111183159B (zh) | 靶向cd137的抗体及其使用方法 | |
| JP7219265B2 (ja) | 抗アペリン抗体及びその使用 | |
| HK1215035A1 (zh) | 人源化抗cd134(ox40)抗體及其應用 | |
| US9328173B2 (en) | Multifunctional antibodies binding to EGFR and MET | |
| CA2837473A1 (en) | Human antigen binding proteins that bind to a complex comprising .beta.-klotho and an fgf receptor | |
| CN102027015A (zh) | 抗cxcr4抗体 | |
| CN111741975B (zh) | 抗血管生成素-2抗体及其用途 | |
| TW202317644A (zh) | 一種含抗ｐｖｒｉｇ／ｔｉｇｉｔ雙特異性抗體的醫藥組成物 | |
| CN117940453A (zh) | 特异性结合pd-1的蛋白及其医药用途 | |
| TW202327649A (zh) | Ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白聯合免疫檢查點抑制劑用於治療癌症 | |
| JP2015525075A (ja) | Ｃａ２１５に対するヒト化抗体 | |
| JP2024505195A (ja) | 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法 | |
| WO2021032174A1 (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
| JP2022531894A (ja) | がんの処置において使用するための抗ｄｒ５抗体の組み合わせの投与レジメン | |
| CN116199777B (zh) | 抗hNKG2D抗体及其应用 | |
| CN120437287A (zh) | 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物 | |
| WO2025056013A1 (zh) | 一种包含特异性结合gprc5d和cd3的双特异性抗体的药物组合物 | |
| WO2024188331A1 (zh) | 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途 | |
| CN120019073A (zh) | 一种治疗实体瘤的方法 |